X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6560) 6560
Newsletter (165) 165
Book Chapter (88) 88
Newspaper Article (63) 63
Magazine Article (30) 30
Dissertation (9) 9
Conference Proceeding (5) 5
Publication (2) 2
Web Resource (2) 2
Reference (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4877) 4877
science & technology (4807) 4807
life sciences & biomedicine (4605) 4605
metformin (4327) 4327
female (3060) 3060
metformin - therapeutic use (2887) 2887
male (2633) 2633
diabetes mellitus, type 2 - drug therapy (2593) 2593
hypoglycemic agents - therapeutic use (2531) 2531
diabetes (2172) 2172
middle aged (2055) 2055
type 2 diabetes (1937) 1937
metformin - adverse effects (1919) 1919
hypoglycemic agents - adverse effects (1872) 1872
endocrinology & metabolism (1710) 1710
aged (1594) 1594
adult (1479) 1479
metformin - administration & dosage (1180) 1180
diabetes mellitus (1150) 1150
hypoglycemic agents - administration & dosage (1106) 1106
insulin (1101) 1101
drug therapy, combination (1092) 1092
treatment outcome (1047) 1047
glucose (932) 932
diabetes therapy (922) 922
risk factors (898) 898
drug therapy (895) 895
care and treatment (894) 894
diabetes mellitus, type 2 - blood (867) 867
insulin resistance (866) 866
pharmacology & pharmacy (864) 864
research (804) 804
hypoglycemic agents (767) 767
animals (704) 704
metformin - pharmacology (670) 670
blood glucose - metabolism (653) 653
analysis (638) 638
clinical trials (631) 631
general & internal medicine (626) 626
double-blind method (623) 623
health aspects (601) 601
medicine, general & internal (590) 590
dosage and administration (567) 567
abridged index medicus (555) 555
diabetes mellitus, type 2 - complications (549) 549
blood glucose - drug effects (537) 537
hypoglycemic agents - pharmacology (509) 509
glycated hemoglobin a - metabolism (498) 498
endocrine system diseases (495) 495
internal medicine (486) 486
sulfonylurea compounds - therapeutic use (473) 473
nutritional and metabolic diseases (471) 471
obesity (455) 455
patients (455) 455
medicine & public health (453) 453
dextrose (451) 451
insulin - therapeutic use (451) 451
body mass index (437) 437
thiazolidinediones - therapeutic use (433) 433
adolescent (424) 424
complications and side effects (420) 420
pregnancy (420) 420
acidosis, lactic - chemically induced (402) 402
aged, 80 and over (387) 387
type 2 diabetes mellitus (380) 380
hypoglycemia (377) 377
young adult (371) 371
studies (370) 370
mortality (358) 358
medical research (349) 349
metabolism (344) 344
body weight (341) 341
cancer (330) 330
glycated hemoglobin a - analysis (326) 326
hyperglycemia (322) 322
medicine (320) 320
oncology (320) 320
retrospective studies (316) 316
thiazolidinediones (308) 308
polycystic ovary syndrome - drug therapy (304) 304
drugs (299) 299
glycosylated hemoglobin (297) 297
polycystic ovary syndrome (292) 292
time factors (291) 291
diabetes mellitus - drug therapy (281) 281
hypoglycemia - chemically induced (280) 280
diabetics (278) 278
randomized controlled trials as topic (276) 276
dipeptidyl-peptidase iv inhibitors - therapeutic use (274) 274
hemoglobin (273) 273
research article (269) 269
administration, oral (268) 268
sulfonylurea compounds - adverse effects (266) 266
medicine, experimental (263) 263
obstetrics & gynecology (255) 255
endocrinology (254) 254
diabetes mellitus, type 2 - metabolism (253) 253
usage (253) 253
drug administration schedule (249) 249
metformin - pharmacokinetics (248) 248
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6631) 6631
German (85) 85
French (65) 65
Spanish (63) 63
Dutch (22) 22
Japanese (19) 19
Chinese (16) 16
Danish (15) 15
Italian (12) 12
Portuguese (12) 12
Swedish (11) 11
Russian (10) 10
Norwegian (9) 9
Czech (8) 8
Polish (6) 6
Korean (5) 5
Hungarian (4) 4
Turkish (4) 4
Finnish (3) 3
Bulgarian (1) 1
Persian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CA: a cancer journal for clinicians, ISSN 0007-9235, 06/2010, Volume 60, Issue 4, pp. 207 - 221
Journal Article
Diabetes care, ISSN 1935-5548, 08/2018, Volume 41, Issue 8, pp. 1543 - 1556
The progressive nature of type 2 diabetes (T2D) requires practitioners to periodically evaluate patients and intensify glucose-lowering treatment once glycemic... 
Humans | Insulin/administration & dosage | Treatment Outcome | Dipeptidyl-Peptidase IV Inhibitors/administration & dosage | Sodium-Glucose Transporter 2/antagonists & inhibitors | Hypoglycemic Agents/administration & dosage | Signal Transduction/drug effects | Metformin/administration & dosage | Animals | Diabetes Mellitus, Type 2/drug therapy | Blood Glucose/drug effects | Thiazolidinediones/administration & dosage | Sulfonylurea Compounds/administration & dosage | Drug Therapy, Combination | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Insulin - administration & dosage | Sodium-Glucose Transporter 2 Inhibitors | Sulfonylurea Compounds - adverse effects | Thiazolidinediones - administration & dosage | Thiazolidinediones - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Metformin - adverse effects | Blood Glucose - drug effects | Hypoglycemic Agents - administration & dosage | Signal Transduction - drug effects | Sulfonylurea Compounds - administration & dosage | Metformin - administration & dosage | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Type 2 diabetes | Usage | Analysis | Practice guidelines (Medicine) | Hypoglycemic agents | Dosage and administration | Drug therapy, Combination | Drug therapy | Risk factors | Index Medicus
Journal Article
Scientific reports, ISSN 2045-2322, 01/2016, Volume 6, Issue 1, pp. 18904 - 18904
A meta-analysis was conducted to assess the clinical efficacy and safety of dulaglutide in patients with type 2 diabetes mellitus (T2DM). Medline, Embase,... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Glycated Hemoglobin A - metabolism | Humans | Body Weight - drug effects | Immunoglobulin Fc Fragments - administration & dosage | Insulin - blood | Metformin - adverse effects | Peptides - administration & dosage | Insulin Glargine - administration & dosage | Hypoglycemic Agents - administration & dosage | Hypoglycemia - physiopathology | Patient Safety | Venoms - administration & dosage | Hypoglycemia - blood | Metformin - administration & dosage | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Sitagliptin Phosphate - administration & dosage | Insulin Glargine - adverse effects | Venoms - adverse effects | Treatment Outcome | Randomized Controlled Trials as Topic | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Hypoglycemia - etiology | Liraglutide - adverse effects | Liraglutide - administration & dosage | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Sitagliptin Phosphate - adverse effects | Diabetes mellitus | Body weight | Clinical trials | Body weight loss | Diabetes | Metformin | Hypoglycemia | Insulin | Index Medicus
Journal Article
Best Practice & Research: Clinical Endocrinology & Metabolism, ISSN 1521-690X, 2007, Volume 21, Issue 4, pp. 517 - 533
... when glucose levels during the two conditions are matched. This is defined as the incretin effect, which is attributed to the intestinal hormones which are released... 
Endocrinology & Metabolism | treatment | dipeptidyl peptidase 4 | sitagliptin | type-2 diabetes | vildagliptin | glucagon-like peptide-1 | Life Sciences & Biomedicine | Science & Technology | Triazoles - adverse effects | Metformin - therapeutic use | Humans | Body Weight - drug effects | Pyrrolidines - adverse effects | Substrate Specificity | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Pyrrolidines - therapeutic use | Thiazolidinediones - therapeutic use | Adamantane - therapeutic use | Sitagliptin Phosphate | Drug Therapy, Combination | Hypoglycemia - chemically induced | Protease Inhibitors - therapeutic use | Insulin Secretion | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Pioglitazone | Insulin - metabolism | Animals | Dipeptidyl-Peptidase IV Inhibitors | Lipid Metabolism - drug effects | Pyrazines - adverse effects | Glucagon - metabolism | Vildagliptin | Glucagon-Like Peptide 1 - antagonists & inhibitors | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Insulin - therapeutic use | Nitriles - therapeutic use | Index Medicus | Clinical Medicine | Other Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Adamantane/adverse effects Adamantane/analogs & derivatives Adamantane/therapeutic use Animals Antigens | Annan klinisk medicin | Combination Glucagon/secretion Glucagon-Like Peptide 1/antagonists & inhibitors Glucagon-Like Peptide 1/physiology Humans Hypoglycemia/chemically induced Hypoglycemic Agents/therapeutic use Insulin/secretion Insulin/therapeutic use Lipid Metabolism/drug effects Metformin/therapeutic use Nitriles/adverse effects Nitriles/therapeutic use Protease Inhibitors/therapeutic use Pyrazines/adverse effects Pyrazines/therapeutic use Pyrrolidines/adverse effects Pyrrolidines/therapeutic use Substrate Specificity Thiazolidinediones/therapeutic use Triazoles/adverse effects Triazoles/therapeutic use | Type 2/drug therapy Drug Therapy | Klinisk medicin | CD26/antagonists & inhibitors Body Weight/drug effects Diabetes Mellitus
Journal Article
Diabetes care, ISSN 1935-5548, 08/2014, Volume 37, Issue 8, pp. 2149 - 2158
Journal Article
Journal Article
Endocrine, ISSN 1559-0100, 11/2016, Volume 57, Issue 3, pp. 464 - 473
To compare the effect of liraglutide, sitagliptin and insulin glargine added to standard therapy on left ventricular function in post-ischemic type-2 diabetes mellitus... 
Type 2 diabetes | Glucagon-like peptide-1 | Medicine & Public Health | Science, Humanities and Social Sciences, multidisciplinary | Left ventricular ejection fraction | Cardiac function | Internal Medicine | Diabetes | Chronic heart failure | Endocrinology | Liraglutide | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Metformin - therapeutic use | Diabetic Cardiomyopathies - drug therapy | Humans | Middle Aged | Heart Failure - physiopathology | Ventricular Dysfunction, Left - complications | Male | Heart Failure - blood | Diabetic Cardiomyopathies - physiopathology | Metformin - adverse effects | Cardiotonic Agents - therapeutic use | Hypoglycemia - prevention & control | Drug Therapy, Combination - adverse effects | Ventricular Dysfunction, Left - blood | Cardiotonic Agents - adverse effects | Female | Diabetic Cardiomyopathies - blood | Diabetes Mellitus, Type 2 - complications | Heart - physiopathology | Hypoglycemic Agents - therapeutic use | Heart Failure - complications | Hyperglycemia - prevention & control | Insulin Glargine - adverse effects | Sulfonylurea Compounds - therapeutic use | Insulin Glargine - therapeutic use | Stroke Volume - drug effects | Biomarkers - blood | Sulfonylurea Compounds - adverse effects | Ventricular Dysfunction, Left - physiopathology | Heart Failure - drug therapy | Diabetes Mellitus, Type 2 - blood | Pilot Projects | Ventricular Dysfunction, Left - drug therapy | Liraglutide - adverse effects | Incretins - adverse effects | Liraglutide - therapeutic use | Heart - drug effects | Quality of Life | Sitagliptin Phosphate - therapeutic use | Aged | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Sitagliptin Phosphate - adverse effects | Heart failure | Usage | Care and treatment | Electrocardiogram | Electrocardiography | Dosage and administration | Index Medicus
Journal Article